LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Summary Public Assessment Report

Fluttasino
(fluticasone propionate)

SE/H/2497/01/DC

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

Summary Public Assessment Report

Fluttasino
fluticasone propionate

Nasal drops, suspension, 400 mikrogram

This is a summary of the public assessment report (PAR) for Fluttasino. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Fluttasino and what is it used for?

The product is a 'hybrid medicine'. This means that it is similar to a reference medicine containing the same active substance.

The reference medicine for the product is Flutide Nasal.

Fluttasino nasal drops are used to treat:
- small growths inside the nose (polyps)
- symptoms associated with nasal obstruction.

Fluttasino nasal drops are provided in small plastic containers.

How does Fluttasino work?

This medicine contains fluticasone propionate. This belongs to a group of medicines called steroids (also called 'corticosteroids').
- steroids work by reducing inflammation
- they reduce swelling and irritation in your nose
- this helps to relieve itching, sneezing and your blocked or runny nose.

How is Fluttasino used?
The pharmaceutical form is nasal drops.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Fluttasino have been shown in studies?

Because the product is a hybrid application and is considered to be similar to the reference product Flutide Nasal, the benefits and risks are taken as being the same as those of the reference medicine.

What are the possible side effects from Fluttasino?

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Fluttasino approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is similar to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Flutide Nasal, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Fluttasino?
A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

For more details, please see the full PAR for Fluttasino on the following website: MRI - Home.

Other information about Fluttasino
The full PAR for Fluttasino can be found on the following website: MRI - Home. For more information about treatment with Fluttasino, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-11.